Abstract
In the respiratory tract, NO is produced by residential and inflammatory cells. NO is generated via oxidation of L-arginine that is catalysed by the enzyme NO synthase (NOS). NOS exists in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO derived from the constitutive isoforms of NOS (nNOS and eNOS) and other NO-adduct molecules (nitrosothiols) are able to modulate bronchomotor tone. NO derived from the inducible isoform of NO synthase, up-regulated by different cytokines via NF-kB-dependent pathway, seems to be a proinflammatory mediator with immunomodulatory effects. The production of NO under oxidative stress conditions secondarily generates strong oxidising agents (reactive nitrogen species) that may amplify the inflammatory response in asthma and COPD. Moreover, NO can be exhaled and levels are abnormal in stable atopic asthma and during exacerbations in both asthma and COPD. Exhaled NO might therefore be a non-invasive tool to monitor the underlying inflammatory process. It is suggested that NOS regulation provides a novel target in the prevention and treatment of chronic inflammatory diseases of the airways such as asthma and COPD.
Keywords: Nitric oxide, nNOS, iNOS, eNOS, asthma, COPD, nitrosothiols, exhaled NO
Current Drug Targets
Title: Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Volume: 7 Issue: 6
Author(s): Fabio L.M. Ricciardolo, Frans P. Nijkamp and Gert Folkerts
Affiliation:
Keywords: Nitric oxide, nNOS, iNOS, eNOS, asthma, COPD, nitrosothiols, exhaled NO
Abstract: In the respiratory tract, NO is produced by residential and inflammatory cells. NO is generated via oxidation of L-arginine that is catalysed by the enzyme NO synthase (NOS). NOS exists in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO derived from the constitutive isoforms of NOS (nNOS and eNOS) and other NO-adduct molecules (nitrosothiols) are able to modulate bronchomotor tone. NO derived from the inducible isoform of NO synthase, up-regulated by different cytokines via NF-kB-dependent pathway, seems to be a proinflammatory mediator with immunomodulatory effects. The production of NO under oxidative stress conditions secondarily generates strong oxidising agents (reactive nitrogen species) that may amplify the inflammatory response in asthma and COPD. Moreover, NO can be exhaled and levels are abnormal in stable atopic asthma and during exacerbations in both asthma and COPD. Exhaled NO might therefore be a non-invasive tool to monitor the underlying inflammatory process. It is suggested that NOS regulation provides a novel target in the prevention and treatment of chronic inflammatory diseases of the airways such as asthma and COPD.
Export Options
About this article
Cite this article as:
Ricciardolo L.M. Fabio, Nijkamp P. Frans and Folkerts Gert, Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435290
DOI https://dx.doi.org/10.2174/138945006777435290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Predicting Drug Efficacy Using Integrative Models for Chronic Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Effects of Cissampelos sympodialis Eichl. and its Alkaloid, Warifteine, in an Experimental Model of Respiratory Allergy to Blomia tropicalis
Current Drug Targets The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Advances in Encoding of Colloids for Combinatorial Libraries: Applications in Genomics, Proteomics and Drug Discovery
Current Pharmaceutical Biotechnology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry High-dimensional Causal Mediation Analysis with a Large Number of Mediators Clumping at Zero to Assess the Contribution of the Microbiome to the Risk of Bacterial Pathogen Colonization in Older Adults
Current Bioinformatics Probiotics and Oral Health
Current Pharmaceutical Design How to Prevent Postpartum Relapse to Smoking
Current Pediatric Reviews The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Complementary, Alternative and Integrative Medicine for Childhood Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery T and B-cell Epitopes Prediction of Iranian Saffron (Crocus sativus) Profilin by Bioinformatics Tools
Protein & Peptide Letters